Essential Pharma, an international specialty pharma group, has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd., a clinical stage pharmaceutical company focused on the development of life-changing therapies in pediatric rare disease.   Renaissance Pharma’s lead asset is Hu14.18K322A (Hu14.18) – an immunotherapy currently in Phase II clinical development for the treatment of high-risk neuroblastoma (HRNB).   The acquisition adds a second product candidat...